Document is current
Any future updates will be listed below
-
Authors
Gardner, Daphne S. L. https://orcid.org/0000-0001-5349-7442
Saboo, Banshi https://orcid.org/0000-0001-7293-8864
Kesavadev, Jothydev https://orcid.org/0000-0001-6522-6391
Mustafa, Norlaila https://orcid.org/0000-0002-0196-7091
Villa, Michael https://orcid.org/0000-0003-0181-3719
Mahoney, Edward
Bajpai, Shailendra
-
Funding
Funding for this research was provided by:
Nippon Becton Dickinson Company
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 13 January 2025
First Online: 10 February 2025
Declarations
:
: Daphne S.L. Gardner received speaker fees and honorarium from Roche, Sanofi, BD/embecta, Abbott Diabetes Care, Medtronic, and NovoNordisk. Received advisory fees from BD/Embecta, DKSH and NovoNordisk. Michael Villa received speaker fees and honorarium from Bayer. Edward Mahoney and Shailendra Bajpai are employees and stockholders of BD/embecta (formerly BD Diabetes Care), manufacturer of a range of safety-engineered devices. No potential conflict of interest relevant to this article was reported by Banshi Saboo, Jothydev Kesavadev, and Norlaila Mustafa.
: Ethical approval was not applicable or required as this article is based on previously conducted studies and does not contain any new data from experiments on human participants or animals performed by any of the authors.
